Abstract
Carboplatin 400 mg/m2 per month was evaluated as a single agent in 15 patients with multiple myeloma who had had one prior chemotherapy regimen. All but three were judged to have had some degree of refractoriness to prior therapy. Hematologic toxicity was frequent and sometimes severe. There were no responses. Further evaluation of standard-dose single-agent carboplatin in refractory myeloma does not appear warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 196-198 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1994 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Carboplatin in previously treated multiple myeloma: A cancer and leukemia group B phase II trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS